Second edition. Edited by Razelle Kurzrock and Moshe Talpaz. 679 pp., illustrated. London, Martin Dunitz, 1999. $139.95. ISBN 1-85317-676-1.
As oncology changes from a largely empirical endeavor to a sciencein which diagnosis and therapy are guided and, indeed, definedby the genetic alterations in a patient's tumor, books suchas this one will become increasingly important. The ultimatenecessity will be to move from simplistic classifications oftumors according to histologic features or alleged organ oforigin toward an understanding of tumors as the result of thecombinatorial action of deregulated or mutated genes. For thisreason, molecular oncology will need to establish an efficientformat to convey its core information: methods of defining whichgenes are important . . . [Full Text of this Article]
Previous
